Celltrion’s Remsima SC gets EMA approval, plans to launch in 2020
IndustryNov 26, 2019
Celltrion said Tuesday its infliximab biobetter Remsima SC has received the European Medicines Agency’s approval for sales in the continent. Remsima SC’s main target patients are those who are resistant to original TNF-a inhibitors such as Humira (adalimumab) and Enbrel (etanercept). While infliximab currently takes up only 9 percent of the rheumatoid arthritis treatment market, the rate of patients who are prescribed a different medication -- apart from adalimumab and etanerce